Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DEVALINGAM MAHALINGAM

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1164650859
CMS profile
795015
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$45,930.34

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $25,867.79 30
E.R. Squibb & Sons, L.L.C. $16,658.16 16
EISAI INC. $3,346.00 4
AVEO Pharmaceuticals, Inc. $58.39 1

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DEVALINGAM MAHALINGAM

NPI 1164650859 · CMS profile ID 795015

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164650859?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DEVALINGAM MAHALINGAM, NPI 1164650859, CMS profile ID 795015. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164650859?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DEVALINGAM MAHALINGAM, NPI 1164650859, CMS profile ID 795015. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164650859?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DEVALINGAM MAHALINGAM, NPI 1164650859, CMS profile ID 795015, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1164650859?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $45,930.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $1,980.0003/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932460959 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $85,604.15 74
PY2020 $19,882.25 27
PY2021 $4,730.00 4
PY2022 $45,930.34 51
PY2023 $43,745.05 36
PY2024 $24,065.39 23
PY2025 $27,573.92 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,157,231.41 158
PY2024 Principal investigator $1,246,014.21 87
PY2023 Principal investigator $1,601,093.92 167
PY2022 Recipient $18,183.41 1
PY2022 Principal investigator $1,050,780.93 65
PY2021 Principal investigator $581,968.86 29
PY2020 Principal investigator $548,176.56 14
PY2019 Principal investigator $663,345.70 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

158 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $18,409.37 12/31/2025 Non-covered Recipient Entity
Northwestern University - Robert H. Lurie Comprehensive Cancer Center
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippel-Lindau VHL Disease-Associate No dispute reported 06/30/2026 1232934802
Principal investigator 1 Merck Sharp & Dohme LLC $18,409.37 12/31/2025 Non-covered Recipient Entity
Northwestern Medicine Cancer Center - Warrenville
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippel-Lindau VHL Disease-Associate No dispute reported 06/30/2026 1232934850
Principal investigator 1 Merck Sharp & Dohme LLC $62,167.80 12/31/2025 Non-covered Recipient Entity
Northwestern Medicine Cancer Center - Warrenville
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippel-Lindau VHL Disease-Associate No dispute reported 06/30/2026 1232934852
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,103.97 12/12/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268492
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,500.00 12/12/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268494
Principal investigator 1 ABBVIE INC. $2,257.20 11/27/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525952
Principal investigator 1 ABBVIE INC. $2,364.12 11/27/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525962
Principal investigator 1 ABBVIE INC. $6,531.47 11/27/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525964
Principal investigator 1 ABBVIE INC. $1,869.12 11/27/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525966
Principal investigator 1 ABBVIE INC. $2,807.64 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519059
Principal investigator 1 ABBVIE INC. $2,807.64 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519061
Principal investigator 1 ABBVIE INC. $2,364.12 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519073
Principal investigator 1 ABBVIE INC. $4,741.44 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519075
Principal investigator 1 ABBVIE INC. $4,575.23 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519077
Principal investigator 1 ABBVIE INC. $2,807.64 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519079
Principal investigator 1 ABBVIE INC. $6,531.47 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519081
Principal investigator 1 ABBVIE INC. $1,842.72 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519083
Principal investigator 1 ABBVIE INC. $2,257.20 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519479
Principal investigator 1 ABBVIE INC. $1,869.12 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519497
Principal investigator 1 ABBVIE INC. $2,807.64 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519499
Principal investigator 1 ABBVIE INC. $2,807.64 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519533
Principal investigator 1 ABBVIE INC. $2,257.20 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519535
Principal investigator 1 ABBVIE INC. $1,869.12 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519537
Principal investigator 1 ABBVIE INC. $4,741.44 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519539
Principal investigator 1 ABBVIE INC. $2,257.20 10/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202519541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38,553.17 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268468
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268470
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,980.00 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268472
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $27,072.60 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268474
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268476
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268478
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268480
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 10/03/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268482
Principal investigator 1 ABBVIE INC. $2,807.64 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512618
Principal investigator 1 ABBVIE INC. $1,869.12 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512620
Principal investigator 1 ABBVIE INC. $2,418.24 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512630
Principal investigator 1 ABBVIE INC. $2,807.64 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512632
Principal investigator 1 ABBVIE INC. $2,807.64 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512634
Principal investigator 1 ABBVIE INC. $2,257.20 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512636
Principal investigator 1 ABBVIE INC. $6,531.47 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512642
Principal investigator 1 ABBVIE INC. $1,869.12 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512652
Principal investigator 1 ABBVIE INC. $2,807.64 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512724
Principal investigator 1 ABBVIE INC. $2,807.64 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512726
Principal investigator 1 ABBVIE INC. $5,380.32 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512728
Principal investigator 1 ABBVIE INC. $2,807.64 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512736
Principal investigator 1 ABBVIE INC. $1,869.12 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512738
Principal investigator 1 ABBVIE INC. $4,741.44 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512740
Principal investigator 1 ABBVIE INC. $6,531.47 09/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512742
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,069.20 09/26/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268466
Principal investigator 1 BioNTech SE $2,427.30 09/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020281
Principal investigator 1 ABBVIE INC. $6,531.47 09/01/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506697
Principal investigator 1 ABBVIE INC. $1,869.12 09/01/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506735
Principal investigator 1 ABBVIE INC. $6,531.47 09/01/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506737
Principal investigator 1 ABBVIE INC. $6,531.47 09/01/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506841
Principal investigator 1 ABBVIE INC. $5,380.32 09/01/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506855
Principal investigator 1 ABBVIE INC. $4,575.23 09/01/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506857
Principal investigator 1 Merck Sharp & Dohme LLC $165,780.48 08/31/2025 Non-covered Recipient Entity
Northwestern University - Robert H. Lurie Comprehensive Cancer Center
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippel-Lindau VHL Disease-Associate No dispute reported 06/30/2026 1232934848
Principal investigator 1 BioNTech SE $1,365.00 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020085
Principal investigator 1 BioNTech SE $15,523.59 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020279
Principal investigator 1 BioNTech SE $18,932.43 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020283
Principal investigator 1 BioNTech SE $337.50 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020285
Principal investigator 1 BioNTech SE $5,940.00 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020287
Principal investigator 1 BioNTech SE $2,500.00 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020289
Principal investigator 1 BioNTech SE $24,500.00 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020291
Principal investigator 1 BioNTech SE $2,504.80 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020293
Principal investigator 1 BioNTech SE $5,126.00 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020295
Principal investigator 1 BioNTech SE $6,125.00 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020297
Principal investigator 1 BioNTech SE $1,320.00 08/26/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020299
Principal investigator 1 Epizyme, Inc. $3,483.75 07/22/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies No dispute reported 06/30/2026 1184282040
Principal investigator 1 ABBVIE INC. $5,694.48 06/27/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493395
Principal investigator 1 BioNTech SE $3,278.70 06/24/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020277
Principal investigator 1 BioNTech SE $3,278.70 06/05/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020275
Principal investigator 1 ABBVIE INC. $5,694.48 05/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486387
Principal investigator 1 ABBVIE INC. $6,024.48 05/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486389
Principal investigator 1 BioNTech SE $1,564.20 05/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020273
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,314.22 05/23/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223280280
Principal investigator 1 Epizyme, Inc. $5,522.88 05/12/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies No dispute reported 06/30/2026 1184282038
Principal investigator 1 ABBVIE INC. $4,575.23 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202479937
Principal investigator 1 ABBVIE INC. $4,575.23 04/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202479979
Principal investigator 1 BioNTech SE $3,077.10 04/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020271
Principal investigator 1 BioNTech SE $18,391.50 04/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020269
Principal investigator 1 ABBVIE INC. $440.88 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468065
Principal investigator 1 ABBVIE INC. $1,980.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468069
Principal investigator 1 ABBVIE INC. $779.09 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468073
Principal investigator 1 ABBVIE INC. $5,687.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468077
Principal investigator 1 ABBVIE INC. $858.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468089
Principal investigator 1 ABBVIE INC. $20,273.68 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468093
Principal investigator 1 ABBVIE INC. $5,687.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468096
Principal investigator 1 ABBVIE INC. $5,687.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468100
Principal investigator 1 ABBVIE INC. $440.88 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468125
Principal investigator 1 ABBVIE INC. $5,687.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468129
Principal investigator 1 ABBVIE INC. $1,750.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468132
Principal investigator 1 ABBVIE INC. $440.88 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468137
Principal investigator 1 ABBVIE INC. $440.88 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468141
Principal investigator 1 ABBVIE INC. $440.88 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468145
Principal investigator 1 ABBVIE INC. $5,687.00 04/02/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202468150
Principal investigator 1 BioNTech SE $14,010.30 04/01/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020267
Principal investigator 1 ABBVIE INC. $5,694.48 03/31/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467287
Principal investigator 1 ABBVIE INC. $2,364.12 03/31/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467297
Principal investigator 1 BioNTech SE $13,359.60 03/25/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020265
Principal investigator 1 BioNTech SE $23,584.50 03/19/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020263
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38,689.57 03/19/2025 Covered Recipient Teaching Hospital
NORTHWESTERN LAKE FOREST HOSPITAL
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223268456
Principal investigator 1 BioNTech SE $9,099.00 03/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020261
Principal investigator 1 ABBVIE INC. $7,076.63 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455065
Principal investigator 1 ABBVIE INC. $2,807.64 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455069
Principal investigator 1 ABBVIE INC. $1,733.16 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455073
Principal investigator 1 ABBVIE INC. $1,842.72 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455077
Principal investigator 1 ABBVIE INC. $2,807.64 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455081
Principal investigator 1 ABBVIE INC. $2,257.20 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455086
Principal investigator 1 ABBVIE INC. $1,869.12 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455093
Principal investigator 1 ABBVIE INC. $4,741.44 02/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455097
Principal investigator 1 BioNTech SE $16,229.70 02/25/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020259
Principal investigator 1 Genentech, Inc. $54,740.70 02/14/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
My Pathway No dispute reported 06/30/2026 1211631766
Principal investigator 1 BioNTech SE $45,939.60 02/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020257
Principal investigator 1 BioNTech SE $21,680.50 02/05/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT411-01 No dispute reported 06/30/2026 1249020253
Principal investigator 1 BioNTech SE $64,932.30 02/05/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT411-01 No dispute reported 06/30/2026 1249020255
Principal investigator 1 ABBVIE INC. $5,380.32 01/29/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202441970
Principal investigator 1 BioNTech SE $540.90 01/21/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020251
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $15,840.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209517
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $5,821.20 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209519
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $5,821.20 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209521
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209523
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,320.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209525
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209527
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209529
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209531
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209533
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209535
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209537
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $15,840.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209539
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209541
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209543
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $5,821.20 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209545
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209547
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209549
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209551
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,750.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209553
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209555
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $779.09 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209557
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209559
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209561
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $5,821.20 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209563
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $325.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209565
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209567
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209569
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209571
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,320.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209573
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $858.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209575
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209577
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209579
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209581
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $5,821.20 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209583
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209585
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $779.09 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209587
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $858.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209589
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $500.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209591
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,750.00 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
Not supplied No dispute reported 06/30/2026 1250209593
Principal investigator 1 BioNTech SE $7,248.60 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
BNT152-01C No dispute reported 06/30/2026 1249020249